Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

Библиографические подробности
Главные авторы:	Moran, A, Ramakrishnan, S, Borg, C, Connolly, C, Couillard, S, Mwasuku, C, Pavord, I, Hinks, T, Lehtimaki, L
Формат:	Conference item
Язык:	English
Опубликовано:	European Respiratory Society 2020

Схожие документы

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
по: Moran, AM, и др.
Опубликовано: (2020)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
по: Shrimanker, R, и др.
Опубликовано: (2017)

Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis
по: Charlene Desaintjean, и др.
Опубликовано: (2024-03-01)

Glucocorticoids and mepolizumab in eosinophilic asthma.
по: Bel, E, и др.
Опубликовано: (2014)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
по: Andrea Portacci, и др.
Опубликовано: (2023-10-01)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
по: Bel, E, и др.
Опубликовано: (2014)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
по: S. K. Zyryanov, и др.
Опубликовано: (2020-12-01)

Mepolizumab in refractory eosinophilic asthma.
по: Pavord, I, и др.
Опубликовано: (2010)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
по: Arian Ghassemian, и др.
Опубликовано: (2021-01-01)

Mepolizumab, quality of life, and severe eosinophilic asthma.
по: Pavord, I
Опубликовано: (2017)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
по: Haldar, P, и др.
Опубликовано: (2009)

Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma
по: Howell, I, и др.
Опубликовано: (2024)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
по: Erminia Ridolo, и др.
Опубликовано: (2020-10-01)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
по: Kayser MZ, и др.
Опубликовано: (2021-07-01)

Mepolizumab treatment in patients with severe eosinophilic asthma.
по: Ortega, H, и др.
Опубликовано: (2014)

Mepolizumab for eosinophilic COPD
по: Sciurba, F, и др.
Опубликовано: (2018)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
по: Osamu Matsuno, и др.
Опубликовано: (2019-01-01)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
по: Yancey, S, и др.
Опубликовано: (2016)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
по: Menzella F, и др.
Опубликовано: (2016-06-01)

Reductions in Eosinophil Biomarkers by Benralizumab in Patients With Asthma
по: Mirhojjat Khorasanizadeh, и др.
Опубликовано: (2017-07-01)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
по: Gómez-Bastero Fernández A, и др.
Опубликовано: (2022-05-01)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
по: Gunsoy, N, и др.
Опубликовано: (2017)

Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
по: Laura J. Walsh, и др.
Опубликовано: (2023-01-01)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
по: Alistair Cook, и др.
Опубликовано: (2021-05-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
по: Howell, I, и др.
Опубликовано: (2024)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
по: Imran Howell, и др.
Опубликовано: (2024-07-01)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
по: Stephen G. Noorduyn, и др.
Опубликовано: (2021-12-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
по: Francesco Menzella, и др.
Опубликовано: (2016-12-01)

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
по: Couillard, S, и др.
Опубликовано: (2021)

Asthma in pregnancy: An update
по: Couillard, S, и др.
Опубликовано: (2020)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
по: Shrimanker, R, и др.
Опубликовано: (2017)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
по: Ortega, H, и др.
Опубликовано: (2016)

Clinical outcomes with mepolizumab therapy in routine practice in the oxford cohort
по: Gittins, A, и др.
Опубликовано: (2018)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
по: Steven W. Yancey, и др.
Опубликовано: (2019-09-01)

Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab
по: Lisha Li, и др.
Опубликовано: (2021-06-01)

Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma
по: Kohei Somekawa, и др.
Опубликовано: (2024-12-01)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
по: Andrew Menzies-Gow, и др.
Опубликовано: (2019-09-01)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
по: Shrimanker, R, и др.
Опубликовано: (2018)

Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis
по: Oliver, ME, и др.
Опубликовано: (2021)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
по: Carlos Martínez-Rivera, и др.
Опубликовано: (2021-01-01)